Epistem Announces Tuberculosis Diagnostic Collaboration

04-Jul-2011 - United Kingdom

EpiStem plc announced the formation of a tuberculosis (TB) diagnostic collaboration with Xcelris Laboratories, one of India's Genomics research and Diagnostic testing companies. Epistem and Xcelris will be evaluating Epistem's Genedrive(TM) molecular device as part of India's RNTCP (Revised National Tuberculosis Control Programme) which started in 1997 and since 2006 has covered the whole of India to ensure the rapid diagnosis and treatment of TB sufferers.

The TB evaluation programme with Xcelris will continue through 2011, following which it is anticipated that it will be rolled out into a select number of remote locations prior to a full evaluation of market positioning.

Other news from the department business & finance

Most read news

More news from our other portals

Recognise, understand, heal: The World of Diagnostics

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper